Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Exelixis, Inc.

< Previous 1 2 3 4 5 Next >
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
From Exelixis, Inc.
Via Business Wire
Tickers CTLT EXEL
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.